Another problem: as many as 30 percent of people enrolled in Alzheimer's studies based on symptoms didn't actually have the disease -- they had other forms of dementia or even other medical conditions. That doesn't give an accurate picture of whether a potential treatment might help, and the new definition aims to improve patient selection by using brain scans and other tests.
In 2014, the WHO annual measles update was titled "Measles deaths reach record lows with fragile gains toward global elimination." It's safe to say that these headlines are a thing of the past since the organization had worse news this time around. In 2018, the WHO estimates that 140,000 people died of measles worldwide, the highest number since 2013. In 2000, as many as 562,000 people were dying of the disease. This number was significantly reduced by vaccination programs.
Not unlike Tolstoy's remark about happy versus unhappy families, current wisdom in vascular biology holds that healthy blood vessels are mostly similar, whereas vessels in different vascular diseases are mostly different. But is this really the case? An evaluation of the literature suggests that unresolved vascular remodeling may be a key element of virtually all vascular diseases. This commonality raises the possibility of unifying principles that govern vascular remodeling and the possibility that methods to restore normal remodeling could effectively treat multiple disease states.
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient's progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients. Scientists at The Neuro (Montreal Neurological Institute and Hospital) of McGill University and the Ludmer Centre for Neuroinformatics and Mental Health used an AI algorithm to analyze the blood and post-mortem brain samples of 1969 patients with Alzheimer's and Huntington's disease. Their goal was to find molecular patterns specific to these diseases. The algorithm was able to detect how these patients' genes expressed themselves in unique ways over decades.
PARIS – It's a devastating disease driving a dementia epidemic ruining tens of millions of lives, but with no new medical treatment since the turn of the century the fight against Alzheimer's is foundering. Despite decades of research and hundreds of millions of dollars, the precise cause of the neurodegenerative disease -- which leaves victims suffering from memory loss, disorientation and behavioral problems -- remains poorly understood. "It's a bit like solving a jigsaw puzzle without knowing what the end result needs to look like," said Pierre Tariot, director of the Banner Alzheimer's Institute in Phoenix, Arizona. This year alone, pharmaceutical giants -- including Lundbeck, Takeda, Merck & Co., Janssen Biotech, AstraZeneca and Eli Lilly -- have either halted or failed in their search for a new Alzheimer's drug. U.S. drug giant Pfizer said in January it was abandoning all research into the disease.